Roti Giovanni

Dr. Roti Giovanni

Department of Medicine and Surgery, University of Parma, Parma, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2024 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
Luca PagliaroLuca Pagliaro
Luca Pagliaro
SCSai-Juan Chen
Sai-Juan Chen
DHDaniel Herranz Herranz
Daniel Herranz Herranz
CMCristina Mecucci
Cristina Mecucci
CHChristine J. Harrison
Christine J. Harrison
RGRoti Giovanni
Roti Giovanni

1 March 2013 in Cancer Cell
Verified
Journal Article
Closed access
RGRoti Giovanni
Roti Giovanni
ACAnne Carlton
Anne Carlton
KRKenneth N. Ross
Kenneth N. Ross
MMMichele Markstein
Michele Markstein
KPKostandin Pajcini
Kostandin Pajcini
KSKimberly Stegmaier
Kimberly Stegmaier

Verified
Journal Article
Open access
PDF file
EFElena Follini
Elena Follini
MMMatteo Marchesini
Matteo Marchesini
RGRoti Giovanni
Roti Giovanni
Chemoresistance is a major cause of recurrence and death from T-cell acute lymphoblastic leukemia (T-ALL), both in adult and pediatric patients. In the majority of cases, drug-resistant disease is treated by selecting a combination of other drugs, without understanding the molecular mechanisms by which malignant cells escape chemotherapeutic treatments, even though a more detailed genomic characterization and the identification of actionable disease targets may enable informed decision of new agents to improve patient outcomes. In this work, we describe pathways of resistance to common chemotherapeutic agents including glucocorticoids and review the resistance mechanisms to targeted therapy such as IL7R, PI3K-AKT-mTOR, NOTCH1, BRD4/MYC, Cyclin D3: CDK4/CDK6, BCL2 inhibitors, and selective inhibitors of nuclear export (SINE). Finally, to overcome the limitations of the current trial-and-error method, we summarize the experiences of anti-cancer drug sensitivity resistance profiling (DSRP) approaches as a rapid and relevant strategy to infer drug activity and provide functional information to assist clinical decision one patient at a time.

6 January 2021 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
LPLuca Pagliaro
Luca Pagliaro
MMMatteo Marchesini
Matteo Marchesini
RGRoti Giovanni
Roti Giovanni
P-type ATPase inhibitors are among the most successful and widely prescribed therapeutics in modern pharmacology. Clinical transition has been safely achieved for H+/K+ATPase inhibitors such as omeprazole and Na+/K+-ATPase inhibitors like digoxin. However, this is more challenging for Ca2+-ATPase modulators due to the physiological role of Ca2+in cardiac dynamics. Over the past two decades, sarco-endoplasmic reticulum Ca2+-ATPase (SERCA) modulators have been studied as potential chemotherapy agents because of their Ca2+-mediated pan-cancer lethal effects. Instead, recent evidence suggests that SERCA inhibition suppresses oncogenic Notch1 signaling emerging as an alternative to γ-secretase modulators that showed limited clinical activity due to severe side effects. In this review, we focus on how SERCA inhibitors alter Notch1 signaling and show that Notch on-target-mediated antileukemia properties of these molecules can be achieved without causing overt Ca2+cellular overload.


7 May 2020 in Cell Chemical Biology
Verified
Journal Article
Closed access
MMMatteo Marchesini
Matteo Marchesini
AGAndrea Gherli
Andrea Gherli
AMAnna Montanaro
Anna Montanaro
LPLaura Patrizi
Laura Patrizi
CSClaudia Sorrentino
Claudia Sorrentino
RGRoti Giovanni
Roti Giovanni